Comment
Author: Admin | 2025-04-28
Tell us what do you think about our website? Logo WELCOME TO ASICA Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: A randomised patient-focused trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma What is ASICA? ASICA is a research study to help understand how technology can be used to support people who have had skin cancer. The ASICA study is looking at how the NHS might use technology in the future to more effectively support people who have been treated for melanoma.The incidence of melanoma has increased over four times since the late 1970s. Approximately 20% of patients treated for a melanoma experience a recurrence and 4-8% may develop a new melanoma. The risk of having a recurrence or developing a new melanoma is highest in the first five years after initial treatment. Current UK melanoma treatment guidelines recommend that all people treated for melanoma attend regular hospital follow-up appointments to help detect any recurrences or new melanomas that may have developed as soon as possible. Patients are also advised to regularly examine their own skin (total-skin-self-examinations) as some studies have found that most recurrences and new primaries are detected by patients between scheduled follow-up visits. Can I take part? You may be eligible to take part in ASICA if: You are aged 18 or over, Have been treated for stage 0-2C primary cutaneous melanoma within the last 60 months, The hospital you have been referred to is taking part in the ASICA study. If you would like any more information about ASICA, including information about taking part please contact the study office at the University of Aberdeen on 01224 438199 or email xrs-asica@abdn.ac.uk. If you are interested in taking part, or have any questions Where can I take part? Key people: Investigator: Address: Key people: Investigator: Dr Nigel Burrows Address: Hills RoadCambridge CB2 0QQ Study news Key facts about the study and documents Key facts about the study and documents If you are eligible and would like to take part, your local hospital team will send you information about the ASICA study.To take part you will be asked to sign a consent form and asked some questions about your health. After this you will be randomised to receive either the ASICA app in addition to your existing melanoma follow-ups, or continue with your existing melanoma follow-ups without the ASICA app.We will follow your progress for 12 months and send you a confidential study questionnaire through the post or by your preferred method at 3, 6 and 12 months to ask about your health and any recurrence or new melanomas. The questionnaires can be returned to the study office in
Add Comment